poisar

Stocks · News reference

MannKind And Rose Pharma Enter Into Worldwide Licensing And Collaboration Agreement To Develop ROSE-010 Technosphere For Weight Management

Benzinga Newsdesk

Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind’s Technosphere® inhalation technologyMannKind to receive an equity interest and potential royalties while providing

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

MNKD
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    MannKind to Participate in the Chardan Healthcare Conference

    MannKind Corporation announced that CEO Michael Castagna will participate in a panel discussion on innovation in chronic respiratory diseases at the Chardan Healthcare Conference on October 20, 2026. The company will also conduct one-on-one investor meetings. MannKind is a biopharmaceutical company focused on cardiometabolic and orphan lung diseases, with treatments addressing diabetes, pulmonary hypertension, and fluid overload conditions.

    MNKD